Colonia Therapeutics' CEO argues that lentiviral delivery is ideal for oncology's required long-term persistence, while LNP delivery is better suited for autoimmune indications needing transient, multi-dose responses. This frames them as complementary technologies for different therapeutic "swim lanes" rather than as direct rivals in a zero-sum game.

Data from J&J's Majestic 3 trial suggests its off-the-shelf bispecific combination could rival the efficacy of its own blockbuster CAR-T, Carvykti. This sets up an internal competition where a more accessible therapy could challenge a complex, personalized one in earlier lines of treatment.

Eli Lilly’s acquisition of in-vivo CAR-T company Colonia Therapeutics signals a deliberate strategy to bypass the crowded and still unproven allogeneic cell therapy space. By investing directly in technology that modifies T-cells inside the body, Lilly is betting it can leapfrog the current generation of cell therapies toward a more scalable platform.

Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.

Scaling manufacturing and commercialization for an autologous CAR-T therapy like Carvykti is too complex for a small biotech alone. Legend Biotech's partnership with J&J was critical, combining Legend's science with J&J's global manufacturing, clinical development, and commercial muscle.

By acquiring both Kelonia (lentivirus) and Orna (RNA-based), Eli Lilly is strategically hedging its bets. This portfolio approach anticipates that different in vivo CAR-T delivery mechanisms will be optimal for different applications, such as durable lentivirus for cancer versus faster-acting RNA for autoimmune diseases.

Despite claims of AI driving massive cost savings, industry experts like Eric Topol predict big pharma will not acquire major AI drug discovery companies in 2026. The dominant strategy is to build capabilities internally and form partnerships, signaling a cautious 'build and partner' approach over outright acquisition.

J&J overcame skepticism about Legend's impressive but China-based CAR-T data by conducting deep, on-the-ground due diligence. They reviewed patient records and documentation to confirm the data's integrity, which became the foundation for a highly successful global partnership.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.